GSK-3

GSK-3β Inhibitor XI is a selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β) with a potent Ki value of 25 nM. This compound enhances glycogen synthase (GS) activity, making it valuable for investigations into metabolic disorders such as type 2 diabetes and neurodegenerative diseases, including Alzheimer’s disease. Its specificity and potency render it a useful tool for elucidating the role of GSK-3β in various biological processes and therapeutic contexts.

SAR502250 is a potent and selective ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3) with an IC50 of 12 nM for human GSK-3β. This compound is orally active and exhibits the ability to penetrate the blood-brain barrier. SAR502250 demonstrates antidepressant-like activity and is applicable for research into Alzheimer's disease and related neurological conditions.

ABC1183 is a selective dual inhibitor targeting GSK3 and CDK9, effectively inhibiting GSK3β, GSK3α, and CDK9/cyclin T1 with IC50 values of 657 nM, 327 nM, and 321 nM, respectively. This compound exhibits notable anti-inflammatory and anti-tumor activities, making it a valuable tool for cancer research and inflammation-related studies. Its ability to modulate critical signaling pathways positions ABC1183 as a promising candidate for further investigation in therapeutic applications.

GSK3β Inhibitor II is a selective inhibitor targeting glycogen synthase kinase 3 beta (GSK3β). This compound exhibits significant activity in modulating GSK3β activity, making it a valuable tool for studying signaling pathways implicated in neurodegenerative diseases such as Alzheimer’s disease. Its use facilitates research aimed at elucidating the roles of GSK3β in cellular processes and potential therapeutic strategies for AD.

(R)-BRD3731 is a selective glycogen synthase kinase 3 (GSK3) inhibitor. It demonstrates inhibitory activity with IC50 values of 1.05 μM for GSK3β and 6.7 μM for GSK3α. This compound is utilized in research focused on understanding GSK3's role in various cellular processes and diseases, including diabetes, neurodegenerative disorders, and cancer. As a valuable tool for studying GSK3 modulation, (R)-BRD3731 facilitates the exploration of therapeutic strategies that target this kinase.

GSK3-IN-9 is a selective inhibitor of glycogen synthase kinase 3 (GSK3). This compound exhibits notable biological activity in neurodevelopmental and psychiatric disorders, including Fragile X syndrome and attention deficit hyperactivity disorder (ADHD). Additionally, GSK3-IN-9 shows potential applicability in research related to childhood seizures, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and other psychiatric disorders.

GSK3-IN-2 is a potent inhibitor of glycogen synthase kinase 3 (GSK3), a key regulator of various cellular processes, including metabolism, cell differentiation, and apoptosis. This compound selectively inhibits GSK3 activity, leading to increased levels of β-catenin and modulation of Wnt signaling pathways. GSK3-IN-2 is valuable for research in cancer biology, neurodegenerative diseases, and regenerative medicine, where GSK3's role in cellular signaling and function is of significant interest.

GS87 is a selective GSK3 inhibitor, demonstrating IC50 values of 415 nM for GSK3α and 521 nM for GSK3β. It effectively activates GSK3-dependent signaling pathways, including MAPK signaling, leading to differentiation of acute myeloid leukemia (AML) cell lines. GS87 exhibits superior modulation of key GSK3 target proteins associated with cell proliferation and differentiation compared to alternative GSK3 inhibitors. This compound holds promise as a differentiation agent for research involving non-promyelocytic AML.

Antitrypanosomal agent 14 is a selective inhibitor of TbGSK3, demonstrating an IC50 of 12 μM and an EC50 of 0.47 μM against Trypanosoma brucei. This compound is primarily utilized in research focused on Human African trypanosomiasis, aiding in the exploration of therapeutic strategies against this parasitic infection. Its targeted mechanism suggests potential for further studies in drug development and disease management.

AKI-062a is a non-selective inhibitor targeting CK1γ and GSK3β, key regulators in the WNT signaling pathway. It exhibits an ability to modulate various kinase activities, binding to 17 kinases at 1 μM concentration, with a relative activity of less than 10% compared to controls. This compound is valuable for research applications related to cell signaling, cancer biology, and developmental processes where WNT signaling is involved.

AChE/BACE1/GSK3β-IN-1 is a potent triple inhibitor targeting acetylcholinesterase (AChE), beta-secretase 1 (BACE1), and glycogen synthase kinase 3 beta (GSK3β). It demonstrates effective inhibitory activity with IC50 values of 1.0 μM for AChE, 20 μM for BACE1, and 15 μM for GSK3β. With favorable blood-brain barrier penetrability and bioavailability, AChE/BACE1/GSK3β-IN-1 is a valuable tool for research into Alzheimer's disease mechanisms and therapeutics.

GSK3-IN-4 is a potent glycogen synthase kinase 3 (GSK3) inhibitor, specifically designed to modulate GSK3 activity. This compound has demonstrated significant biological activity relevant to the study of psychiatric disorders, making it a valuable tool for exploring the molecular mechanisms underlying these conditions. GSK3-IN-4's inhibition of GSK3 opens avenues for therapeutic research and the development of novel treatments targeting neurological diseases.

GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies.

CHIR-98023 is a selective and reversible inhibitor of glycogen synthase kinase 3 (GSK3), demonstrating IC50 values of 10 nM for GSK3α and 6.7 nM for GSK3β. This compound enhances insulin signaling and glucose metabolism, making it valuable for research in diabetes and metabolic disorders. Its specificity for GSK3 further supports its potential in elucidating the pathways associated with cell signaling and energy homeostasis.

GSK3β-IN-4 is a potent and selective ATP-competitive inhibitor of GSK3β, exhibiting an IC50 of 0.37 nM. This compound also shows activity against GSK3α with an IC50 of 2.75 nM and a selectivity index of 7.4. GSK3β-IN-4 effectively reduces tau phosphorylation at Ser396 and has demonstrated improvements in cognitive deficits in Alzheimer's disease models. It is suitable for research focused on Alzheimer's disease pathophysiology and potential therapeutic interventions.

Aloisine RP106 is a potent inhibitor of cyclin-dependent kinases (CDKs) Cdk1/cyclin B and Cdk5/p25, as well as glycogen synthase kinase 3 (GSK3), with IC50 values of 0.70 µM, 1.5 µM, and 0.92 µM, respectively. This compound is valuable for research applications targeting cell cycle regulation and neurodegenerative diseases, where CDK and GSK3 activity contribute to pathological processes. Researchers can utilize Aloisine RP106 to investigate the role of these kinases in various biological contexts including cancer and neurobiology.

PfGSK3/PfPK6-IN-2 is a potent dual inhibitor of PfGSK3 and PfPK6, with IC50 values of 172 nM and 11 nM, respectively. This compound exhibits significant efficacy in the modulation of key signaling pathways in Plasmodium falciparum, making it a valuable tool for malaria research. Its ability to inhibit these targets can aid in the investigation of therapeutic strategies against malaria.

PfGSK3/PfPK6-IN-1 is a selective inhibitor targeting PfGSK3 and PfPK6, with IC50 values of 97 nM and 8 nM, respectively. This compound effectively inhibits the proliferation of blood-stage Plasmodium falciparum 3D7 parasites, making it a valuable tool for malaria research. Additionally, PfGSK3/PfPK6-IN-1 exhibits low cytotoxicity in hepatocyte cultures at concentrations up to 200 nM, with a significant reduction in cell viability observed at 2 μM. Its dual action enhances its potential in studying malaria-related mechanisms and potential therapeutic strategies.

SGK1-IN-8 is a potent inhibitor of SGK1 and GSK3β, exhibiting an IC50 of 0.11 μM against human SGK1 and 3.39 μM against human GSK3β. This compound effectively inhibits the catalytic activities of both SGK1 and GSK3β, leading to a reduction in the phosphorylation of the TAU protein at the Ser214 site. SGK1-IN-8 is utilized in research focused on Alzheimer's disease and related neurodegenerative disorders.